Ellevest, Inc. Intellia Therapeutics, Inc. Transaction History

Ellevest, Inc.

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 04, 2023	BUY	$33.3 - $44.82 $9,290 - $12,504	279 New	279 $10,000
Q4 2022 Feb 03, 2023	SELL	$33.21 - $62.69 $697 - $1,316	-21 Closed	0 $0
Q3 2022 Nov 02, 2022	BUY	$53.92 - $71.7 $647 - $860	12 Added 133.33%	21 $1,000
Q2 2022 Jul 18, 2022	SELL	$38.49 - $76.21 $962 - $1,905	-25 Reduced 73.53%	9 $0
Q1 2022 Apr 19, 2022	SELL	$58.27 - $118.99 $174 - $356	-3 Reduced 8.11%	34 $2,000
Q4 2021 Jan 24, 2022	SELL	$100.76 - $138.36 $3,224 - $4,427	-32 Reduced 46.38%	37 $4,000
Q3 2021 Oct 19, 2021	BUY	$132.37 - $176.78 $1,985 - $2,651	15 Added 27.78%	69 $9,000
Q2 2021 Jul 13, 2021	SELL	$60.88 - $161.91 $2,252 - $5,990	-37 Reduced 40.66%	54 $9,000
Q1 2021 May 03, 2021	BUY	$46.59 - $83.68 $2,143 - $3,849	46 Added 102.22%	91 $7,000
Q4 2020 Feb 04, 2021	BUY	$18.83 - $63.53 $357 - $1,207	19 Added 73.08%	45 $2,000
Q3 2020 Oct 26, 2020	BUY	$17.47 - $24.93 $139 - $199	8 Added 44.44%	26 $1,000
Q2 2020 Jul 06, 2020	SELL	$11.14 - $22.87 $33 - $68	-3 Reduced 14.29%	18 $0
Q1 2020 Apr 13, 2020	SELL	$9.44 - $15.58 $349 - $576	-37 Reduced 63.79%	21 $0
Q4 2019 Feb 05, 2020	BUY	$10.43 - $17.67 $604 - $1,024	58 New	58 $1,000

314

91.5M

442K

880K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $926M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Ellevest, Inc., based on Form 13F filings with the SEC.

Stay updated on Ellevest, Inc. with notifications on news.